chartexchange

Nuvation Bio Reports Third Quarter 2026 Financial Results and Provides Business Update

PR Newswire | Nov 4, 2026 4:05 PM EST

Achieved $45.0 million in third quarter 2026 total revenue, including $27.5 million in net product revenue for IBTROZI® (taletrectinib) IBTROZI continues to be the most prescribed ROS1 TKI and established as the ROS1 market leader in new patient starts and total active patients for both...

Read original article